



Massachusetts Society of Addiction Medicine

A Chapter of American Society of Addiction Medicine

OFFICERS

President

Jessica Gray, MD

President-Elect

Heidi Ginter, MD

Immediate Past President

James Baker, MD, MPH

Treasurer

Ruth A. Potee, MD, DFASAM, FAAFP

Secretary

Daniel Liauw, MD, MPH

Director of Education

Maria Quinn, MSN, PMHNP-BC

Director of Advocacy

Joshua St. Louis, MD, MPH, AAHIVS

May 22, 2026

Re: MASAM's Support for H. 2200, An Act Relative to the Prescription Drug Program

Dear Honorable State Lawmakers,

On behalf of the Massachusetts Society of Addiction Medicine (MASAM), the leading medical specialty society representing physicians and other clinicians in Massachusetts who treat substance use disorders, we write today in support of H. 2200. This important legislation would allow individuals receiving methadone treatment from opioid treatment programs (OTPs) to be included in the prescription monitoring program (PMP).

PMPs are an important tool to protect patients and ensure proper prescribing of controlled substances. However, medications dispensed by OTPs are not currently included in our state's PMP,¹ despite compelling evidence for their inclusion. For example, the American Society of Addiction Medicine (ASAM) recommends that methadone and buprenorphine dispensed by OTPs be included in PMPs.² As ASAM's public policy statement notes, PMPs can be used to promote public health, protect patients, and reduce the risk of overdose. H. 2200 would take a step in the right direction by allowing individuals receiving methadone treatment from OTPs to be included in PMPs.

As addiction medicine specialists, we know the key role that PMPs play to inform prescribing practices and protect public health. Our board in particular wishes to highlight that one of our members, Dr. Ruth Potee, oversees one of the largest OTP networks in the state of Massachusetts (Behavioral Health Network) and strongly support this legislation. It is hard to imagine more well-informed expertise than hers. For these reasons, we are proud to support H. 2200 and urge lawmakers to cosponsor the bill. We also commend the sponsors for their leadership in bringing forward this important legislation.

Thank you for considering our perspective. Please reach out to us if you have any questions. We are happy to assist. Our board also wishes to note an interest in recommending certain textual changes related to the avoidance of stigmatizing language should such recommendations be appropriate.

Sincerely,

Jessica Gray, MD

President, Massachusetts Society of Addiction Medicine (MASAM)

¹ Prescription Monitoring Program Data in Massachusetts. Mass.gov. <https://www.mass.gov/info-details/prescription-monitoring-program-data-in-massachusetts>

² ASAM - American Society of Addiction Medicine. (2023). Refocusing Prescription Drug Monitoring Programs (PDMPs) to Serve Public Health. [https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2023/07/28/refocusing-prescription-drug-monitoring-programs-\(pdmps\)-to-serve-public-health](https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2023/07/28/refocusing-prescription-drug-monitoring-programs-(pdmps)-to-serve-public-health)